4 ms·
Or, in the case of albuterol inhalers, the companies can actively lobby to prevent the older version from being distributed anymore. Evergreening is absolutely
by pessimizer 7y ago
Or, in the case of albuterol inhalers, the companies can actively lobby to prevent the older version from being distributed anymore.
Evergreening is absolutely a thing, and absolutely planned and executed by the companies that profit from it.
- deleted 7y ago[deleted]
- pg_bot 7y agoThe older albuterol inhalers are no longer sold because they used CFCs as a propellant. CFC usage was banned internationally by the Montreal protocol in 1987. The propellant could not be immediately replaced due to strict FDA safety guarantees so they carved out a temporary exemption for medical usage. Research and development was done to find a replacement (HFAs) and that work is now being paid for by the patents granted from that process (more expensive inhalers). Whether this was a valid trade-off is a separate discussion but company lobbying is not the reason why they are no longer distributed. https://www.fda.gov/drugs/questions-answers/transition-cfc-propelled-albuterol-inhalers-hfa-propelled-albuterol-inhalers-questions-and-answers https://www.fda.gov/drugs/questions-answers/transition-cfc-p...
- tptacek 7y agoI think his point is that evergreening isn't a feature of the patent system; there's no mechanism to extend a patent, and "extension" patents of minor modifications don't extend the legal monopoly on a drug, but rather function as a marketing mechanism that preys on the industry's willingness to prescribe whatever the newest iteration of a drug is, regardless of evidence.